Drugs / BPR-30221616
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06760455 | Jan 2025 → Jan 2026 overdue | — | Chengdu Brilliant Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPR-30221616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06760455 ↗ |
| Route | Subcutaneous | “BPR-30221616 will be administered by subcutaneous (SC) injection” NCT06760455 ↗ |